-
1
-
-
0026704779
-
The evolution of hydroxyurea therapy in chronic myelogenous leukemia
-
Kennedy BJ. The evolution of hydroxyurea therapy in chronic myelogenous leukemia. Semin Onc 1992;19(Suppl 9):21-6
-
(1992)
Semin Onc
, vol.19
, Issue.SUPPL. 9
, pp. 21-26
-
-
Kennedy, B.J.1
-
2
-
-
0026778383
-
Mechanism of action of hydroxyurea
-
Yarbro JW. Mechanism of action of hydroxyurea. Semin Onc 1992;19:(Suppl 9):1-10
-
(1992)
Semin Onc
, vol.19
, Issue.SUPPL. 9
, pp. 1-10
-
-
Yarbro, J.W.1
-
3
-
-
0027377963
-
Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit human immunodeficiency virus type 1 replication
-
Gao W-Y, Cara A, Gallo RC, Lori R. Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci 1993;90:8925-8
-
(1993)
Proc Natl Acad Sci
, vol.90
, pp. 8925-8928
-
-
Gao, W.-Y.1
Cara, A.2
Gallo, R.C.3
Lori, R.4
-
4
-
-
0027948936
-
Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication
-
Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994;266:801-5
-
(1994)
Science
, vol.266
, pp. 801-805
-
-
Lori, F.1
Malykh, A.2
Cara, A.3
-
5
-
-
0029086336
-
Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2′,3′-dideoxynucleoside activities against replication of human immunodeficiency virus
-
Gao W-Y, Johns DG, Chokekijchai S, Mitsuya H. Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2′,3′-dideoxynucleoside activities against replication of human immunodeficiency virus. Proc Natl Acad Sci 1995;92:8333-7
-
(1995)
Proc Natl Acad Sci
, vol.92
, pp. 8333-8337
-
-
Gao, W.-Y.1
Johns, D.G.2
Chokekijchai, S.3
Mitsuya, H.4
-
6
-
-
0027976787
-
Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools
-
Meyerhans A, Vartanian J-P, Hultgren C, et al. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J Virol 1994;68:535-40
-
(1994)
J Virol
, vol.68
, pp. 535-540
-
-
Meyerhans, A.1
Vartanian, J.-P.2
Hultgren, C.3
-
7
-
-
7144257857
-
A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection
-
Rutschmann OT, Opravil M, Iten A, et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. AIDS 1998;12:F71-7
-
(1998)
AIDS
, vol.12
-
-
Rutschmann, O.T.1
Opravil, M.2
Iten, A.3
-
8
-
-
0003605027
-
-
Cary, NC: SAS Institute Inc
-
Little RC, Milliken GA, Stroup WW, Wolfinger WD. SAS system for mixed models. Cary, NC: SAS Institute Inc., 1996
-
(1996)
SAS System for Mixed Models
-
-
Little, R.C.1
Milliken, G.A.2
Stroup, W.W.3
Wolfinger, W.D.4
-
9
-
-
0033118835
-
Management of sickle cell disease
-
Steinberg MH. Management of sickle cell disease. N Engl J Med 1999;340:1021-30
-
(1999)
N Engl J Med
, vol.340
, pp. 1021-1030
-
-
Steinberg, M.H.1
-
10
-
-
0030055872
-
Treatment of human immunodeficiency virus infection with hydroxyurea: Virologic and clinical evaluation
-
Giacca M, Zanussi S, Comar M, et al. Treatment of human immunodeficiency virus infection with hydroxyurea: virologic and clinical evaluation. J Infect Dis 1996;174:204-9
-
(1996)
J Infect Dis
, vol.174
, pp. 204-209
-
-
Giacca, M.1
Zanussi, S.2
Comar, M.3
-
12
-
-
0030956535
-
A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus disease receiving chronic didanosine therapy: Canadian HIV Trials Network Protocol 080
-
Montaner JSC, Zala C, Conway B, et al. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus disease receiving chronic didanosine therapy: Canadian HIV Trials Network Protocol 080. J Infect Dis 1997;175:801-6
-
(1997)
J Infect Dis
, vol.175
, pp. 801-806
-
-
Montaner, J.S.C.1
Zala, C.2
Conway, B.3
-
13
-
-
0029086733
-
Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1 infected individuals
-
Biron F, Lucht F, Peyramond D, et al. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1 infected individuals. AIDS Res Hum Retrovir 1995;10: 36-40
-
(1995)
AIDS Res Hum Retrovir
, vol.10
, pp. 36-40
-
-
Biron, F.1
Lucht, F.2
Peyramond, D.3
-
14
-
-
0037708198
-
Antiviral activity and CD4 count responses in patients treated with efavirenz, stavudine, and didanosine, plus hydroxyurea or placebo: 48 Week final results from the 3D study
-
abstract no. LB-09
-
Murphy RL, Katlama C, Bedsey E, et al. Antiviral activity and CD4 count responses in patients treated with efavirenz, stavudine, and didanosine, plus hydroxyurea or placebo: 48 week final results from the 3D study (abstract no. LB-09). In: Program and abstracts of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment 2001:323
-
(2001)
Program and Abstracts of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment
, pp. 323
-
-
Murphy, R.L.1
Katlama, C.2
Bedsey, E.3
-
15
-
-
0035958764
-
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression
-
Havlir DV, Gilbert PB, Bennett K, et al. Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. AIDS 2001;15:1379-88
-
(2001)
AIDS
, vol.15
, pp. 1379-1388
-
-
Havlir, D.V.1
Gilbert, P.B.2
Bennett, K.3
-
16
-
-
0033914469
-
In vivo antagonism with zidovudine plus stavudine combination therapy
-
Havlir DV, Tierney C, Friedland GH, et al. In vivo antagonism with zidovudine plus stavudine combination therapy. J Infect Dis 2000;182:321-5
-
(2000)
J Infect Dis
, vol.182
, pp. 321-325
-
-
Havlir, D.V.1
Tierney, C.2
Friedland, G.H.3
-
17
-
-
0030831543
-
Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance
-
Lori F, Malykh AG, Foli A, et al. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res Hum Retrovir 1997;13:1403-9
-
(1997)
AIDS Res Hum Retrovir
, vol.13
, pp. 1403-1409
-
-
Lori, F.1
Malykh, A.G.2
Foli, A.3
-
18
-
-
0026465275
-
Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine
-
Gu Z, Gao Q, Li X, Parniak MA, Wainberg MA. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J Virol 1992;66:7128-35
-
(1992)
J Virol
, vol.66
, pp. 7128-7135
-
-
Gu, Z.1
Gao, Q.2
Li, X.3
Parniak, M.A.4
Wainberg, M.A.5
-
19
-
-
0028607429
-
Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy
-
Kozal MJ, Kroodsma K, Winters MA, et al. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann Intern Med 1994;121:263-8
-
(1994)
Ann Intern Med
, vol.121
, pp. 263-268
-
-
Kozal, M.J.1
Kroodsma, K.2
Winters, M.A.3
-
20
-
-
0032817241
-
A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance
-
Larder BA, Bloor S, Kemp SD, et al. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob Agents Chemother 1999;43:1961-7
-
(1999)
Antimicrob Agents Chemother
, vol.43
, pp. 1961-1967
-
-
Larder, B.A.1
Bloor, S.2
Kemp, S.D.3
-
21
-
-
0030840407
-
Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy
-
De Antoni A, Foli A, Lisziewicz J, Lori F. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. J Infect Dis 1997;176:899-903
-
(1997)
J Infect Dis
, vol.176
, pp. 899-903
-
-
De Antoni, A.1
Foli, A.2
Lisziewicz, J.3
Lori, F.4
-
22
-
-
0032854838
-
Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates
-
Palmer S, Shafer RW, Merigan TC. Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates. Antimicrob Agents Chemother 1999;43:2046-50
-
(1999)
Antimicrob Agents Chemother
, vol.43
, pp. 2046-2050
-
-
Palmer, S.1
Shafer, R.W.2
Merigan, T.C.3
-
23
-
-
0034056306
-
A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1
-
American Foundation for AIDS Research Community-Based Clinical Trials Network
-
Hellinger JA, Iwane MK, Smith JJ, et al. A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. American Foundation for AIDS Research Community-Based Clinical Trials Network. J Infect Dis 2000;181:540-7
-
(2000)
J Infect Dis
, vol.181
, pp. 540-547
-
-
Hellinger, J.A.1
Iwane, M.K.2
Smith, J.J.3
|